Request Your Free White Paper Now:

"Advancing the Design and Manufacture of Next-Generation Therapeutics"

Download this whitepaper to learn more.

Asimov is developing a synthetic biology platform applied to biologics, viral vectors, and RNA therapeutics to improve manufacturing outcomes through optimized or customized genetic sequences.

One of the biggest challenges Asimov faces is finding a partner who can supply reliable synthesis of DNA fragments for vector construction. Their solution was to turn to Elegen’s ENFINIA™ Linear DNA.

In this case study, learn how Elegen’s cell-free gene synthesis platform :

• Enabled Asimov to take advantage of immediate use of ready-made linear fragments in their plasmid assembly and the cloning pipeline, saving time and money.
• Offers US-based cell-free gene synthesis service with fast turnaround - even for complex and long sequences above 5kb in length.
• Provides long gene fragments with a higher accuracy and purity than other suppliers.

Offered Free by: Elegen
See All Resources from: Elegen